FDA And Generic Drug Quality: Turning Point, Or Precipice?
Executive Summary
OGD Director Geba says generic manufacturers still suffer from extensive quality problems, but GPhA officials argue the industry is doing fine and communications with the agency need to be more uniform.
You may also be interested in...
Drug GMP “Surveillance” Will Link Compliance Information To Inspections
CDER Director Janet Woodcock says a new database will drive risk-based inspection decisions. Once active and combined with new objective quality measurement data, the system should allow all relevant agency personnel access to the same information in the hopes of improving oversight.
Drug GMP “Surveillance” Will Link Compliance Information To Inspections
CDER Director Janet Woodcock says a new database will drive risk-based inspection decisions. Once active and combined with new objective quality measurement data, the system should allow all relevant agency personnel access to the same information in the hopes of improving oversight.
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
CDER’s Woodcock says the new database will drive risk-based inspection decisions.